GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » KORU Medical Systems Inc (NAS:KRMD) » Definitions » 5-Year RORE %

KORU Medical Systems (KORU Medical Systems) 5-Year RORE % : 48.44% (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is KORU Medical Systems 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. KORU Medical Systems's 5-Year RORE % for the quarter that ended in Mar. 2024 was 48.44%.

The industry rank for KORU Medical Systems's 5-Year RORE % or its related term are showing as below:

KRMD's 5-Year RORE % is ranked better than
92.2% of 654 companies
in the Medical Devices & Instruments industry
Industry Median: -1.345 vs KRMD: 48.44

KORU Medical Systems 5-Year RORE % Historical Data

The historical data trend for KORU Medical Systems's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KORU Medical Systems 5-Year RORE % Chart

KORU Medical Systems Annual Data
Trend Feb14 Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 77.16 51.16

KORU Medical Systems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.14 - 39.82 51.16 48.44

Competitive Comparison of KORU Medical Systems's 5-Year RORE %

For the Medical Instruments & Supplies subindustry, KORU Medical Systems's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KORU Medical Systems's 5-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where KORU Medical Systems's 5-Year RORE % falls into.



KORU Medical Systems 5-Year RORE % Calculation

KORU Medical Systems's 5-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.28-0.03 )/( -0.64-0 )
=-0.31/-0.64
=48.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 5-year before.


KORU Medical Systems  (NAS:KRMD) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


KORU Medical Systems 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of KORU Medical Systems's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


KORU Medical Systems (KORU Medical Systems) Business Description

Traded in Other Exchanges
N/A
Address
100 Corporate Drive, Mahwah, NJ, USA, 07430
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on home and specialty infusion solutions. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Executives
Manko Joseph M. Jr. 10 percent owner 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Kenneth E Miller officer: Chief Commercial Officer 26 MOUNTAINVIEW RD, WARREN NJ 07059
Edward Wholihan director C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Linda M Tharby officer: President and CEO BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
Lafrence Andrew D.c. officer: Chief Financial Officer C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas Edward Adams officer: Interim CFO 524 WOODLAND AVENUE, BRIELLE NJ 08730
Brian Case officer: Chief Technology Officer 424 CYPRUS CIR, LAKE VILLA IL 60046-8629
Shahriar Matin director 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Donna French director 25 SEARSVILLE COURT, HILLSBOROUGH CA 94010
Donald B Pettigrew officer: Pres./Chief Commercial Officer 7871 ENGEN LOOP, PARK CITY UT 84098
Karen Fisher officer: CFO 24 CARPENTER ROAD, CHESTER NY 10918
Daniel S Goldberger director 24 CARPENTER ROAD, CHESTER NY 10918
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Horton Freedom, L.p. 10 percent owner 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103